Aramchol

Aramchol is a synthetic conjugate of cholic acid and arachidic acid, developed as a drug candidate for the treatment of nonalcoholic steatohepatitis (NASH). It is a fatty acid bile acid conjugate (FABAC).

Mechanism of action: Aramchol is believed to work by modulating the sterol regulatory element-binding protein (SREBP) pathway, a key regulator of lipid metabolism. Specifically, it aims to reduce steatosis (fat accumulation) in the liver, inflammation, and fibrosis, all hallmarks of NASH. By downregulating SREBP, Aramchol is intended to decrease the synthesis of triglycerides and other lipids in the liver.

Clinical development: Aramchol has undergone several clinical trials to evaluate its safety and efficacy in patients with NASH. Studies have investigated its impact on liver histology, including changes in steatosis, inflammation, and fibrosis scores, as well as its effects on biochemical markers of liver function.

Status: As of late 2023, the development status of Aramchol is uncertain following some reported trial results and strategic decisions by its developer, Galmed Pharmaceuticals. Further investigation of recent announcements is recommended to ascertain current development plans.